Viatris (VTRS) Revenue & Revenue Breakdown

Overview ForecastOwnership Financials Chart Transcripts

Viatris Revenue Highlights

Latest Revenue (Y)

$14.30B

Latest Revenue (Q)

$3.76B

Main Segment (Y)

Brands

Main Geography (Y)

Developed Markets Segment

Viatris Revenue by Period

Viatris Revenue by Year

Date	Revenue	Change
2025-12-31	$14.30B	-2.98%
2024-12-31	$14.74B	-4.46%
2023-12-31	$15.43B	-5.14%
2022-12-31	$16.26B	-9.08%
2021-12-31	$17.89B	49.73%
2020-12-31	$11.95B	3.87%
2019-12-31	$11.50B	0.58%
2018-12-30	$11.43B	-3.98%
2017-12-30	$11.91B	7.50%
2016-12-30	$11.08B	17.47%
2015-12-30	$9.43B	22.15%
2014-12-30	$7.72B	11.73%
2013-12-30	$6.91B	1.66%
2012-12-31	$6.80B	10.87%
2011-12-31	$6.13B	12.46%
2010-12-31	$5.45B	7.02%
2009-12-31	$5.09B	-0.87%
2008-12-31	$5.14B	76.85%
2007-12-31	$2.91B	131.08%
2006-03-31	$1.26B	0.30%
2005-03-31	$1.25B	-8.82%
2004-03-31	$1.37B	24.51%
2002-03-31	$1.10B	30.40%
2001-03-31	$846.70M	7.16%
2000-03-31	$790.14M	9.57%
1999-03-31	$721.10M	36.42%
1998-03-31	$528.60M	20.08%
1997-03-31	$440.20M	12.04%
1996-03-31	$392.90M	-0.81%
1995-03-31	$396.10M	57.31%
1994-03-31	$251.80M	18.77%
1993-03-31	$212.00M	-

Viatris generated $14.30B in revenue during NA 2025, up -2.98% compared to the previous quarter, and up 119.70% compared to the same period a year ago.

Viatris Revenue by Quarter

Date	Revenue	Change
2025-09-30	$3.76B	4.96%
2025-06-30	$3.58B	10.07%
2025-03-31	$3.25B	-7.76%
2024-12-31	$3.53B	-5.95%
2024-09-30	$3.75B	-1.20%
2024-06-30	$3.80B	3.64%
2024-03-31	$3.66B	-4.53%
2023-12-31	$3.84B	-2.65%
2023-09-30	$3.94B	0.59%
2023-06-30	$3.92B	5.08%
2023-03-31	$3.73B	-3.79%
2022-12-31	$3.88B	-4.96%
2022-09-30	$4.08B	-0.94%
2022-06-30	$4.12B	-1.79%
2022-03-31	$4.19B	-3.45%
2021-12-31	$4.34B	-4.30%
2021-09-30	$4.54B	-0.90%
2021-06-30	$4.58B	3.33%
2021-03-31	$4.43B	22.27%
2020-12-31	$3.62B	21.92%
2020-09-27	$2.97B	8.82%
2020-06-28	$2.73B	4.28%
2020-03-29	$2.62B	-17.94%
2019-12-31	$3.19B	7.77%
2019-09-29	$2.96B	3.86%
2019-06-29	$2.85B	14.27%
2019-03-30	$2.50B	-18.94%
2018-12-30	$3.08B	7.56%
2018-09-29	$2.86B	1.93%
2018-06-29	$2.81B	4.61%
2018-03-30	$2.68B	-17.12%
2017-12-30	$3.24B	8.43%
2017-09-29	$2.99B	0.84%
2017-06-29	$2.96B	8.92%
2017-03-30	$2.72B	-16.78%
2016-12-31	$3.27B	6.89%
2016-09-30	$3.06B	19.39%
2016-06-30	$2.56B	16.86%
2016-03-31	$2.19B	-12.02%
2015-12-31	$2.49B	-7.59%
2015-09-30	$2.70B	13.64%
2015-06-30	$2.37B	26.71%
2015-03-31	$1.87B	-10.13%
2014-12-31	$2.08B	-0.06%
2014-09-30	$2.08B	13.43%
2014-06-30	$1.84B	7.09%
2014-03-31	$1.72B	-5.14%
2013-12-31	$1.81B	2.33%
2013-09-30	$1.77B	3.86%
2013-06-30	$1.70B	4.30%
2013-03-31	$1.63B	-4.16%
2012-12-31	$1.70B	-5.93%
2012-09-30	$1.81B	6.99%
2012-06-30	$1.69B	6.23%
2012-03-31	$1.59B	4.00%
2011-12-31	$1.53B	-2.83%
2011-09-30	$1.58B	0.12%
2011-06-30	$1.57B	8.62%
2011-03-31	$1.45B	1.01%
2010-12-31	$1.43B	5.86%
2010-09-30	$1.36B	-0.98%
2010-06-30	$1.37B	5.89%
2010-03-31	$1.29B	-4.40%
2009-12-31	$1.35B	6.94%
2009-09-30	$1.26B	-0.23%
2009-06-30	$1.27B	4.72%
2009-03-31	$1.21B	0.56%
2008-12-31	$1.20B	-27.38%
2008-09-30	$1.66B	37.71%
2008-06-30	$1.20B	11.97%
2008-03-31	$1.07B	-

Viatris generated $3.76B in revenue during Q3 2025, up 4.96% compared to the previous quarter, and up 99.03% compared to the same period a year ago.

Viatris Revenue Breakdown

Viatris Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Brands	$9.18B	$9.20B	$9.80B	$9.89B	-
Generics	$5.07B	$5.49B	$5.59B	$5.02B	-
Product	-	-	-	$16.22B	$17.81B
Complex GX and Biosimilars	-	-	-	$1.31B	-

Viatris's latest annual revenue breakdown by segment (product or service), as of Dec 25: Brands (64.45%), and Generics (35.55%).

Quarterly Revenue by Product

Product/Service	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Generics	$1.34B	$1.31B	$1.28B	$1.13B	$2.77B	$1.38B	$1.34B	$1.23B	-	-	-	-	-	-	-	-	-	-
Brands	$2.35B	$2.44B	$2.28B	$2.12B	$4.53B	$2.36B	$2.31B	$2.53B	-	-	-	-	-	-	-	-	-	-
Xalabrands	-	-	-	-	-	-	$42.50M	$47.90M	$48.40M	$54.00M	$55.80M	$58.30M	$57.90M	-	-	-	-	-
Product and Service, Other	-	-	-	-	-	-	-	-	$9.10M	$10.00M	$8.90M	$10.80M	$11.40M	$13.50M	-	-	-	-

Viatris's latest quarterly revenue breakdown by segment (product or service), as of Dec 25: Brands (63.56%), and Generics (36.44%).

Viatris Revenue Breakdown by Country

Annual Revenue by Country

Country	Dec 25	Dec 24	Dec 23	Dec 22	Dec 21
Japan, Australia and New Zealand Segment	$1.20B	$1.35B	$1.42B	$1.63B	-
Developed Markets Segment	$8.55B	$8.96B	$9.25B	$9.77B	-
Emerging Markets Segment	$2.22B	$2.26B	$2.55B	$2.62B	-
Greater China Segment	$2.33B	$2.17B	$2.16B	$2.20B	-
UNITED STATES	-	-	-	$3.95B	$4.18B
CHINA	-	-	-	$1.95B	$1.98B

Viatris's latest annual revenue breakdown by geography, as of Dec 25: Developed Markets Segment (59.81%), Greater China Segment (16.31%), Emerging Markets Segment (15.51%), and Japan, Australia and New Zealand Segment (8.38%).

Quarterly Revenue by Country

Country	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Mar 24	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21
Developed Markets Segment	$2.26B	$2.27B	$2.13B	$1.90B	$4.50B	$2.30B	$2.17B	-	-	-	-	-	-	-	-	-	-	-
Japan, Australia and New Zealand Segment	$306.60M	$307.30M	$306.70M	$277.10M	$687.60M	$344.30M	$317.80M	-	-	-	-	-	-	-	-	-	-	-
Greater China Segment	$572.90M	$615.20M	$588.90M	$555.50M	$1.06B	$561.80M	$543.90M	$548.40M	$1.60M	$2.20M	$100.00K	$1.90M	$1.70M	$3.40M	$2.70M	-	$1.10M	$1.00M
Emerging Markets Segment	$565.80M	$571.80M	$556.90M	$523.10M	$1.10B	$533.20M	$626.40M	-	-	-	-	-	-	-	-	-	-	-

Viatris's latest quarterly revenue breakdown by geography, as of Dec 25: Developed Markets Segment (60.98%), Greater China Segment (15.47%), Emerging Markets Segment (15.28%), and Japan, Australia and New Zealand Segment (8.28%).

Viatris Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
RDY	Dr. Reddy's Laboratories	$279.16B	-
VTRS	Viatris	$14.30B	$3.76B
ELAN	Elanco Animal Health	$4.71B	$1.14B
EXAS	Exact Sciences	$3.25B	$850.74M
NBIX	Neurocrine Biosciences	$2.86B	$794.90M
MRNA	Moderna	$1.94B	$1.02B
IONS	Ionis Pharmaceuticals	$944.00M	$156.72M
BBIO	BridgeBio Pharma	$362.37M	$108.11M
BAX	Baxter	$352.00M	$2.83B
ROIV	Roivant Sciences	$124.80M	$2.00M
RGC	Regencell Bioscience	-	-

VTRS Revenue FAQ

What is Viatris’s yearly revenue?

Viatris's yearly revenue for 2025 was $14.3B, representing a decrease of -2.98% compared to 2024. The company's yearly revenue for 2024 was $14.74B, representing a decrease of -4.46% compared to 2023. VTRS's yearly revenue for 2023 was $15.43B, representing a decrease of -5.14% compared to 2022.

What is Viatris’s quarterly revenue?

Viatris's quarterly revenue for Q3 2025 was $3.76B, a 4.96% increase from the previous quarter (Q2 2025), and a 0.23% increase year-over-year (Q3 2024). The company's quarterly revenue for Q2 2025 was $3.58B, a 10.07% increase from the previous quarter (Q1 2025), and a -5.65% decrease year-over-year (Q2 2024). VTRS's quarterly revenue for Q1 2025 was $3.25B, a -7.76% decrease from the previous quarter (Q4 2024), and a -11.17% decrease year-over-year (Q1 2024).

What is Viatris’s revenue growth rate?

Viatris's revenue growth rate for the last 3 years (2023-2025) was -7.31%, and for the last 5 years (2021-2025) was -20.05%.

What are Viatris’s revenue streams?

Viatris's revenue streams in c 25 are Brands, and Generics. Brands generated $9.18B in revenue, accounting 64.45% of the company's total revenue, down -0.18% year-over-year. Generics generated $5.07B in revenue, accounting 35.55% of the company's total revenue, down -7.76% year-over-year.

What is Viatris’s main source of revenue?

For the fiscal year ending Dec 25, the largest source of revenue of Viatris was Brands. This segment made a revenue of $9.18B, representing 64.45% of the company's total revenue.